Chai Discovery, an AI drug discovery startup, has secured major partnerships with pharmaceutical giants Pfizer and Eli Lilly to develop new antibody-based therapies using its advanced AI models. Valued at $1.3 billion, Chai recently launched its improved Chai-3 model, which significantly enhances the success rate and binding strength of designed antibodies, attracting Pfizer's interest. The company is also in talks to raise an additional $400 million at a $3.4 billion valuation, aiming to expand its collaborations and accelerate drug development. This progress highlights AI's growing impact on speeding up and improving the precision of drug discovery, potentially transforming the pharmaceutical industry.
The 4-Factor Dividend Growth Strategy, inspired by the Schwab US Dividend Equity ETF (SCHD), targets high-quality dividend stocks using four specific metrics. Since its inception, it has delivered an average 12-month return of 16.94%, outperforming S...
Weight Watchers has partnered with Eli Lilly's digital platform LillyDirect to offer its Med+ program, combining GLP-1 medication access with clinical and behavioral support. This integration aims to provide patients nationwide with a comprehensive w...
Biotech and pharma mergers and acquisitions (M&A) reached $106 billion across 201 deals in early 2026, driven by urgent needs to replace revenue from expiring drug patents and renewed investor interest. Despite rising interest rates and inflation, de...
Major investors are increasingly focusing on AI-driven biology and longevity, with startups like NewLimit tripling in value. While many of these startups remain private, NVIDIA and Eli Lilly stand out as the main public companies involved, partnering...
Eli Lilly reported a 55.5% revenue increase in Q1, driven by strong sales of Mounjaro and Zepbound totaling $12.8 billion. Despite this growth, shares have only risen slightly due to pricing pressures and charges from acquisitions and litigation. The...
